Here is a reality that anyone who has worked in pharmaceutical regulatory affairs knows well: a drug that works can still fail to reach patients — not because the science is weak, but because the submission package that presents that science is poorly structured, inconsistently formatted, or strategically mismanaged. The Common Technical Document exists precisely to prevent that outcome, and understanding it thoroughly is one of the most commercially valuable competencies in the pharmaceutical industry.
The Common Technical Document (CTD) is the internationally harmonised format for pharmaceutical regulatory submissions, developed under the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). Since its adoption, it has become the standard submission format accepted by regulatory authorities across the European Union, Japan, Canada, Australia, and a growing number of Asian and emerging markets. It is not simply a formatting convention — it is a structured argument for why a medicine is safe, efficacious, and of consistent quality, presented in a form that regulators across multiple jurisdictions can navigate efficiently.
📁 The CTD Structure: Five Modules, One Coherent Argument
The CTD is organised into five modules, each serving a distinct and deliberate purpose within the overall submission architecture.
Module 1 — Administrative and Regional Information This module is the only non-harmonised section of the CTD. Its content varies by jurisdiction and includes region-specific administrative documents: application forms, proposed labelling, product information documents, and any locally required regulatory certifications. Because Module 1 requirements differ between markets, it is the section most frequently responsible for administrative rejection at the gateway stage of submission review — a preventable failure that delays approval timelines without any scientific justification.
Module 2 — Summaries and Overviews Module 2 is arguably the most strategically important section of the entire CTD. It contains the Quality Overall Summary (QOS), the Nonclinical Overview and Summaries, and the Clinical Overview and Summaries. These documents do not simply repeat the data contained in Modules 3, 4, and 5 — they interpret it, contextualise it, and present the integrated scientific argument for the product’s approvability. A well-written Module 2 guides the reviewer’s understanding of the full dossier before they encounter the underlying data. A poorly written Module 2 creates confusion, raises unnecessary questions, and slows the review process.
Module 3 — Quality Module 3 contains the complete pharmaceutical development and manufacturing data for the product: drug substance characterisation, manufacturing process description and validation, control of drug substance and drug product, container closure system data, and stability studies. For most small molecule products, Module 3 is the largest section of the CTD by volume. For biologics and advanced therapy medicinal products, its complexity increases substantially.
Module 4 — Nonclinical Study Reports Module 4 contains the full reports from pharmacology, pharmacokinetics, and toxicology studies conducted in non-human systems. These studies establish the scientific foundation for the clinical programme — demonstrating mechanism of action, identifying potential toxicities, and supporting the dose selection rationale for first-in-human studies.
Module 5 — Clinical Study Reports Module 5 is the clinical evidence base for the product: the complete reports from all clinical pharmacology studies, controlled and uncontrolled clinical trials, post-marketing data where applicable, and the integrated summaries of efficacy and safety. For a product with a substantial clinical development programme, Module 5 can contain hundreds of individual study reports and supporting datasets.
📊 The Data on CTD Submission Quality and Approval Outcomes
The relationship between CTD submission quality and regulatory approval outcomes is well documented — and the performance data across Asian and global markets is instructive for any organisation preparing a submission.
A 2024 analysis of pharmaceutical regulatory submissions across eight Asian markets — covering Japan, South Korea, Singapore, Malaysia, Thailand, Indonesia, the Philippines, and Taiwan — found that:
- 43% of initial CTD submissions received a Request for Supplementary Information (RSI) or equivalent major deficiency notice within the first cycle of regulatory review
- Of those deficiency notices, 61% cited issues that were directly attributable to CTD structure, document quality, or data presentation — rather than to underlying scientific deficiencies in the product itself
- Submissions that received a major deficiency notice in the first review cycle experienced an average approval delay of 14.3 months compared to submissions that progressed without a major deficiency notice
- The average cost of a 14-month approval delay — accounting for continued development expenditure, delayed revenue generation, and regulatory response preparation — was estimated at USD 4.2 million per product for mid-sized pharmaceutical companies
The implication is direct: a substantial proportion of regulatory approval delays in Asian markets are not caused by inadequate science. They are caused by inadequate submission quality — and that is a correctable problem.
A separate 2025 benchmarking study of CTD submission outcomes across ICH member jurisdictions found that submissions prepared by dedicated regulatory affairs teams with formal CTD training had a first-cycle approval rate of 67%, compared to 41% for submissions prepared without dedicated regulatory affairs resource. The gap between those two figures represents the commercial value of CTD competency — measured in months of delayed market access and millions of dollars of deferred revenue.
🔍 The eCTD: Digital Submission and Its Growing Dominance
The electronic Common Technical Document (eCTD) is the digital implementation of the CTD format, structured as a hierarchical XML-based file set that allows regulatory authorities to navigate submission content electronically, track submission history across application lifecycles, and manage amendments and variations with version-controlled document management.
eCTD submission is now mandatory in Japan, the European Union, Canada, Australia, and a growing number of Asian markets including South Korea and Singapore. Markets including Malaysia, Thailand, and Indonesia are at various stages of eCTD implementation roadmaps, with mandatory adoption timelines progressively being established.
A 2024 regulatory technology survey of pharmaceutical companies operating across Asia found that:
- 72% of companies with annual revenues above USD 500 million had fully implemented eCTD authoring and publishing systems
- That figure dropped to 34% for companies with annual revenues below USD 100 million — suggesting that eCTD readiness remains a significant operational gap for small and mid-sized pharmaceutical organisations operating in Asian markets
- Companies without established eCTD capability reported an average of 6.2 additional weeks of submission preparation time per dossier compared to companies with mature eCTD systems — a recurring operational inefficiency with direct impact on submission timelines and regulatory affairs resource costs
The transition to eCTD is not a future consideration for pharmaceutical companies operating across Asian markets. For most markets of commercial significance, it is a current operational requirement.
💡 CTD Submission Tips That Actually Make a Difference
Beyond structural compliance, the difference between a CTD submission that progresses smoothly and one that generates a cascade of regulatory questions typically comes down to a small number of consistently observed best practices.
Start Module 2 last, not first. The summaries and overviews in Module 2 should be written after the underlying data in Modules 3, 4, and 5 is finalised — not drafted in parallel and then inconsistently updated. Inconsistencies between Module 2 summaries and the underlying study reports are one of the most frequently cited CTD deficiency categories across all major regulatory markets.
Treat the Quality Overall Summary as a scientific narrative, not a data index. The QOS is not a table of contents for Module 3. It is a coherent scientific argument for the product’s quality, presented in a form that a reviewer can follow without simultaneously cross-referencing the full Module 3 data package. The most effective QOS documents tell the quality story of the product — from development rationale through manufacturing process design to the stability data that supports the proposed shelf life.
Manage cross-references with discipline. The CTD format relies heavily on cross-referencing between sections — a reference in Module 2 to a specific study report in Module 5, for example, or a reference in the QOS to a specific analytical method in Module 3. Broken cross-references, incorrect section citations, and references to documents that do not exist in the submitted dossier are a consistent source of reviewer queries and a straightforward indicator of submission quality management weakness.
Build the submission timeline backwards from the target submission date. CTD compilation is a complex project management exercise involving multiple functional teams — regulatory affairs, clinical, non-clinical, pharmaceutical development, manufacturing, and quality assurance. Submissions that miss target dates or are submitted with incomplete sections almost invariably reflect a timeline that was built forwards from the available data rather than backwards from a defined submission date with clear milestones and functional accountabilities.
Conduct a pre-submission quality review. A structured internal review of the complete CTD package — conducted by a reviewer who was not involved in authoring the submission — before the dossier is submitted to the regulatory authority is one of the highest-return quality investments available to a pharmaceutical regulatory affairs function. A 2024 industry survey found that organisations with a formal pre-submission review process had a 29% lower rate of first-cycle major deficiency notices compared to organisations without such a process.
The Common Technical Document is the primary instrument through which pharmaceutical companies present their case for market authorisation to regulatory authorities around the world. The quality of that instrument — its structure, its internal consistency, its scientific clarity, and its strategic coherence — directly determines how efficiently that case is evaluated, and how quickly a medicine that works reaches the patients who need it.
